NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia.

Micropeptides, proteins under 100 amino acids, are emerging regulators of cancer, metabolism, and neurodegeneration. Learn how ribosome profiling can reveal these hidden proteins, driving the discovery of new biomarkers and development of novel therapeutics.

RNA is unlocking the ability to develop life‑saving therapies at unprecedented speed. The recent success with baby KJ demonstrates how RNA medicine can move a personalized treatment from diagnosis to clinic in less than a year.

Eclipse Bioinnovations, Inc. (Eclipsebio), the leading partner for RNA-based and RNA-targeting therapeutic development, today announced the launch of its eVERSE™ portfolio of AI-ready datasets. eVERSE is a first-in-class collection of datasets generated from all key aspects of RNA biology that inform therapeutic development from target discovery to drug design.

Artificial intelligence (AI) is transforming how we approach RNA research and drug discovery. In this eBlog we review how data is one of the key pillars for the successful use of AI.